Pantothenic Acid (Vitamin B5)

Supplements · §538

The bottle says energy, adrenal support, stress. It's a B vitamin that lives in nearly every food you eat — the name itself, pantothenic, comes from the Greek for "from everywhere" — and no free-living adult on a normal diet has actually been deficient in it since the 1940s prisoner-of-war camps. Supplementing it does not boost energy in a well-fed person, does not "support the adrenals" in any sense an endocrinologist would recognise, and the energy-stack marketing is built on the mechanism word, not the trial data. Three narrow exceptions are real and worth knowing about — a specific derivative for lipids, a topical form for damaged skin, a high oral dose for some acne — and the rest of the shelf is a tax on people who feel vaguely tired.

Know · As-needed Evidence Emerging Chapter Supplements

For most readers this is a money-back entry, not an action entry. The vitamin is everywhere in food, the body defends the inside pools against extra intake, and the "energy" and "adrenal" claims have either been directly tested and failed or were never tested at all. The three carve-outs are honest and small: a different molecule called pantethine drops LDL by around a tenth in adults who can't or won't take a statin; a cream form repairs damaged skin barrier with a seven-decade clinical track record; a gram-scale oral dose helped mild acne in one small trial. Cheap to try, cheap to skip, sharp enough about which is which.

Pantothenic acid's job in the body is one specific thing, and once you understand it you can throw out most of what the supplement aisle says about it. The vitamin is the obligatory raw material for a molecule called coenzyme A, which the body uses as a chemical handle for moving acetyl and fatty-acid fragments around — burning sugar, burning fat, making cholesterol, making cortisol, making the building blocks of cell membranes (IOM 1998). That is genuinely central biochemistry; if you somehow ran out of coenzyme A you would not make energy from anything you ate.

The marketing leans on this — "central to energy metabolism" on the side of the bottle — and then quietly skips the next sentence, which is the one that matters. Tissue levels of coenzyme A are defended by the body, not driven by intake. Once your pools are full, extra pantothenic acid is excreted in urine; cells do not stockpile more cofactor because you swallowed more precursor (IOM 1998). Necessary and limiting are different words. Water is necessary for being alive; drinking eight extra glasses doesn't make you more alive. The shelf treats the vitamin like it's both.

How much you need, and why you already have it

The number to remember is small: about 5 milligrams a day for an adult — roughly what's in a single egg plus a handful of sunflower seeds, or a serving of mushrooms, or a chicken thigh and some yoghurt (IOM 1998). There's no separate "recommended dose" the way there is for vitamin C or D, just an adequate intake — and the reason for that lower-key label is the same reason you've probably never heard of someone being diagnosed with pantothenic acid deficiency: it's so close to impossible on a normal diet that the regulators couldn't gather the human data to set a stricter number (IOM 1998).

The history here is unusually clean. When mid-twentieth-century researchers wanted to study deficiency in humans, they couldn't produce it with diet alone — they had to feed volunteers a chemical that blocks the vitamin's uptake while also withholding it. Only then did the symptoms appear: burning feet, fatigue, stomach trouble, irritability, all of it reversed by re-feeding the vitamin (Hodges 1958). A later study tried to produce deficiency just by restricting intake and, over nine weeks, couldn't — blood levels dropped but no functional symptoms appeared (Fry 1976). The only naturally occurring human deficiency on record is "burning feet syndrome" in Far East prisoners of war in the 1940s, against a background of starvation and multiple coexisting deficiencies (IOM 1998).

This is the foundation for everything that follows. The mechanism is real; the deficiency-risk story is closed; the question worth your attention is whether any of the derivative claims (lipids, skin, acne) actually hold up. The next sections take those one at a time.

The two claims that don't hold up

Two stories sell most of the B₅ bottles on the shelf. Both fail when you check them.

"It supports the adrenals"

The claim traces to mid-twentieth-century rat studies where pantothenate-deficient animals had reduced adrenal output, and supplementation restored it. That's a finding about fixing a deficiency in a rat, not about boosting cortisol production in a well-fed person — and the leap was never tested in humans. The broader frame, "adrenal fatigue," is the part most readers actually encounter, and it's a marketing construct, not a medical entity: a systematic review of every study claiming to demonstrate it found no validated test, no consistent definition, and no evidence the condition exists outside of diagnosed adrenal insufficiency (which is rare and serious and looks nothing like the symptoms the supplement aisle describes) (Cadegiani 2016). Your adrenals make cortisol all day; the rate-limiting input is not how much pantothenic acid you swallowed.

"It gives you energy"

This one has actually been tested. Cyclists were given pantothenic-acid derivatives or placebo and put through standard endurance tests; nothing changed — not their oxygen uptake, not their time-to-exhaustion, not how their bodies handled fuel during exercise (Webster 1997). That's the cleanest single read on whether topping up a non-deficient person makes them feel more energetic, and the answer was no. The afternoon tiredness you're trying to fix is almost certainly sleep, glucose, posture, or just the shape of being a person — not a B₅ shortage.

"Pantethine and pantothenic acid are the same thing"

This one matters in the opposite direction. Pantethine is a sister molecule — close cousin, not twin — and it does something the parent vitamin doesn't: it lowers LDL cholesterol. If you read about "B₅ for cholesterol" online and reach for the standard pantothenic acid bottle, you've grabbed the wrong molecule. The next section is the right one.

The three carve-outs that are real

Three uses of the broader B₅ family genuinely earn shelf space. Each is a different molecule from the standard tablet, each is small, and each is honestly described by the people studying it.

Pantethine for cholesterol — a real but small effect

If you have borderline-high cholesterol and you can't take a statin (or you've decided not to), pantethine is a defensible option. Across a handful of trials going back to the 1980s — Italian cardiology work first, then two cleaner North American studies in the last fifteen years — pantethine at 600 mg a day dropped LDL by around 11% and triglycerides by a bit more over about four months, in adults already on a controlled diet (Gaddi 1984) (Rumberger 2011) (Evans 2014). That's a real effect, replicated across studies, with side effects no different from placebo.

Topical dexpanthenol for damaged skin — the strongest evidence in the family

This is the use with the longest track record by a wide margin. Dexpanthenol is the cream form — the body turns it into pantothenic acid in the skin — and it's been the active ingredient in Bepanthen and equivalents since 1944. It repairs skin barrier, speeds re-epithelialisation after wounds and minor burns, and reduces how much water leaks out of irritated skin; the supporting evidence is a mix of small trials, mechanistic work, and seven decades of clinical experience, summarised in a recent anniversary review (Proksch 2017). A reasonable use case: a fresh tattoo, post-laser or post-shave irritation, eczema patches, a baby's nappy rash, any compromised barrier that needs gentle help.

Oral B₅ for acne — one trial, take it as that

The acne hypothesis came out of Hong Kong in the 1990s with an uncontrolled report at megadoses and large claimed effects (Leung 1995), which is the wrong way around. The right way was a 2014 trial: 48 adults with mild-to-moderate facial acne, randomised to a pantothenic-acid-based supplement at 2.2 grams a day or placebo for twelve weeks. The supplement arm lost about two-thirds of their lesions versus about two-fifths for placebo, with no serious side effects (Yang 2014). That's a meaningful gap.

The honest framing: one small trial, funded by the supplement maker, never replicated, with no settled mechanism. If you've exhausted standard acne first-lines (topical retinoid, benzoyl peroxide, a tested oral antibiotic course) and you want an adjunct with a plausible upside and a very low downside, a twelve-week try at this dose is a reasonable experiment. If you haven't tried the first-line options, do those first — they have far more data behind them.

How safe is it

Unusually safe, and that's part of why the claims persist — when something is hard to harm someone with, the cost of being wrong about whether it works is low, and the placebo response gets to do its work uninterrupted. The IOM declined to set an upper limit at all, because high-dose human exposure showed no consistent toxicity signal beyond occasional diarrhoea at multi-gram doses (IOM 1998).

The one published warning worth carrying: a woman taking very high doses of both biotin and pantothenic acid together — for hair growth, both in the multi-gram range — developed a life-threatening fluid collection around her lungs and heart that resolved when she stopped (Debourdeau 2001). One case report in the modern literature, but the two vitamins share an intestinal transporter, and stacking both at extreme doses is the situation to avoid.

Why people say "I tried B5 and it didn't work" — and they're right

Almost every "B₅ did nothing for me" story traces to one of three predictable patterns:

The expectation was an energy boost. There was nothing to boost — you were already replete. The bottle was selling a mechanism word, not an effect.
The wrong molecule was bought. The reader took calcium pantothenate (the standard supplement form) expecting the lipid effect that only pantethine delivers. Two different molecules with two different stories; the shelf labels them similarly enough to mislead.
The acne improvement was regression to the mean. Acne is famously cyclical; an uncontrolled trial of anything during a flare-and-quiet cycle will look like the thing worked. This is the whole reason the 2014 trial — with a placebo arm — is the data point that matters and the earlier mega-dose reports are not (Yang 2014).

If you're considering trying any of the carve-outs, the cheapest insight is to read the bottle, check the molecule, and pick a trial duration before you start. That's what separates an honest experiment from a slow drift through your wallet.

Adjacent topics worth a look once you've sorted this one:

The "adrenal fatigue" frame more broadly — the language is everywhere; the underlying construct doesn't survive scrutiny. If a practitioner is treating you for it, the wider question is what they're actually treating.
Biotin (vitamin B₇) — shares an intestinal transporter with pantothenic acid and has its own marketing ecosystem (hair, nails) with a similar shape: real biochemistry, weak supplementation case in the replete.
Niacin (B₃) for lipids — the older, larger-effect, less comfortable cousin of pantethine's lipid story. Worth knowing about if you're weighing non-statin options seriously.
Topical retinoids and benzoyl peroxide for acne — the first-line evidence base the B₅ acne trial sits beside, not above.
Multivitamins generally — the same "necessary versus limiting" question runs through most of the B-vitamin shelf.

Substance and claimed effects

Pantothenic acid (vitamin B₅) is a water-soluble B vitamin whose biochemical role is fixed: it is the obligatory precursor for coenzyme A (CoA) and the 4'-phosphopantetheine prosthetic group of acyl carrier protein, two cofactors that sit at the centre of fatty acid synthesis and oxidation, the citric acid cycle, ketogenesis, cholesterol synthesis, steroid hormone synthesis, and acetylation reactions (IOM 1998, Said 2011). The name derives from the Greek pantothen ("from everywhere"), reflecting its near-ubiquitous distribution in plant and animal foods (IOM 1998). The entry holistically covers the consequences named in the brief: CoA synthesis and energy metabolism; lipid markers at high doses (specifically the pantethine derivative, not pantothenic acid per se); the adrenal-support marketing claim; and topical / oral uses for acne and skin barrier. Where claims diverge between the parent vitamin and its derivatives (pantethine, dexpanthenol), the dossier names the form being studied — this is the central editorial wedge, since the lipid and skin literatures rest on derivatives that behave like quite different molecules in vivo.

Evidence by addressing question

mechanism

Science / mechanism. Pantothenic acid is absorbed in the small intestine by the sodium-dependent multivitamin transporter (SMVT, gene SLC5A6) it shares with biotin and lipoate (Said 2011). Cells convert it through a five-step pathway to CoA, with pantothenate kinase as the regulated step. CoA is required for every acetyl- and acyl-transfer reaction in intermediary metabolism — pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, β-oxidation, fatty acid synthase (where 4'-phosphopantetheine is the swinging arm of ACP), HMG-CoA reductase substrate flow, ketogenesis, ω-amino-acid catabolism, and N-/O-acetylations including histone acetylation (IOM 1998). The mechanism explains why a deficient organism cannot make energy from any macronutrient. It does not explain why a sufficient one would benefit from more: once tissue CoA pools are saturated, additional pantothenate is excreted in urine. Endogenous degradation and renal clearance both rise as intake rises, so plasma and urinary pantothenate track recent intake but tissue CoA is homeostatically defended (IOM 1998).

evidence

Science. Experimental deficiency in humans is a 1950s artefact: Hodges and colleagues fed volunteers an antagonist (ω-methyl pantothenic acid) on a pantothenate-free diet and produced burning-feet paraesthesia, fatigue, GI distress, insomnia, and personality changes, with all symptoms reversed by re-feeding pantothenate (Hodges 1958). A later semi-starvation protocol without the antagonist failed to elicit clear clinical signs over nine weeks even at very low intake, with blood pantothenate falling but no functional deficit appearing (Fry 1976). The 1940s reports of "burning feet syndrome" in Far East prisoners of war are the only naturalistic human deficiency on record, and they occurred against a background of multiple coexisting deficiencies (IOM 1998). The Institute of Medicine therefore set an Adequate Intake rather than an RDA — 5 mg/day for adults, 6–7 mg/day in pregnancy and lactation — and declined to set a Tolerable Upper Intake Level because high-dose data showed no toxicity signal (IOM 1998). Typical Western intakes (~4–7 mg/day) sit at or above the AI without supplementation (IOM 1998).

Energy / performance. The cleanest test of the "B vitamins for energy" claim in non-deficient humans is the Webster trial: cyclists supplemented with pantothenic acid derivatives showed no improvement in VO₂max, time-to-exhaustion, or substrate utilisation versus placebo (Webster 1997). This pattern — replete subjects, additional intake, null result — is the consistent finding for B-vitamin ergogenics.

Lipid markers (pantethine). Pantethine is the disulfide dimer of pantetheine, the immediate precursor of 4'-phosphopantetheine and one step closer to CoA than pantothenic acid itself. In Italian observational and small RCT work from the 1980s, pantethine at 900–1200 mg/day reduced total and LDL cholesterol by ~10–15% and triglycerides by ~20–30% in mixed hyperlipidaemias (Gaddi 1984). Two more recent industry-funded but methodologically respectable North American trials replicated the lipid effect at 600 mg/day over 16 weeks in low-to-moderate cardiovascular risk adults already on a controlled diet, with LDL falling by ~11% versus placebo and non-HDL cholesterol by ~8% (Rumberger 2011, Evans 2014). The effect is real but modest — a fraction of what a moderate-intensity statin delivers — and is specific to pantethine; ordinary pantothenic acid at any dose has not been shown to lower lipids in humans.

Topical and oral acne. The original "B₅ cures acne" hypothesis came from Leung, who proposed a regional deficiency model and gave open-label doses of 10 g/day oral pantothenic acid plus topical cream with reported large effects, without a control arm (Leung 1995). The first properly controlled trial used a pantothenic-acid-based supplement at 2.2 g/day for 12 weeks in mild-to-moderate facial acne and reported a significant reduction in total lesion count versus placebo (mean −68% vs −41%) with no serious adverse effects (Yang 2014); n=48, single trial, manufacturer-funded. Topical dexpanthenol — the alcohol analogue of pantothenic acid, converted to pantothenate in skin — has a much larger and older evidence base for skin-barrier repair, acceleration of re-epithelialisation, and reduction of transepidermal water loss in irritated or compromised skin; the bulk of these data are mechanism + small RCTs, summarised in Proksch's anniversary review (Proksch 2017).

protocol

For the underlying vitamin, the operational target is dietary sufficiency, not supplementation. The AI of 5 mg/day is reached by an unremarkable mixed diet: eggs, organ meats, mushrooms, avocado, sunflower seeds, yoghurt, whole grains, and broccoli are particularly dense sources, and the vitamin is widespread enough that a varied diet without any one of them still clears the AI (IOM 1998). Where the reader is targeting a specific derivative effect, dose tracks the form: pantethine for lipids at 600 mg/day in two or three divided doses (Rumberger 2011, Evans 2014); oral pantothenic acid for acne at 2.2 g/day with the caveat of a single small RCT (Yang 2014); topical dexpanthenol 5% cream once or twice daily for compromised skin barrier (Proksch 2017).

misconceptions

"B₅ supports the adrenals." The marketing claim traces to mid-twentieth-century rodent work showing that pantothenate-deficient rats had reduced adrenal cortical activity and that supplementation restored it. The inferential jump — that supplementing replete humans boosts adrenal output, or treats "adrenal fatigue" — is unsupported by any controlled human data. A systematic review of every study purporting to demonstrate adrenal fatigue found no validated test for the construct and no evidence the entity exists outside diagnosed adrenal insufficiency (Cadegiani 2016). Pantothenic acid is genuinely required for the synthesis of cortisol and the catecholamines (as CoA), but synthesis is not rate-limited by intake in replete individuals.

"B₅ gives you energy." CoA is required for energy metabolism; supplementation does not augment energy in the replete. The Webster trial is the cleanest single test of this in humans and was null on every endpoint (Webster 1997). The energy-supplement category leans on the mechanism word for the marketing claim while the actual literature is silent.

"Pantethine and pantothenic acid are interchangeable." They are not. The lipid-lowering effect at 600–1200 mg/day is consistent across pantethine trials but has never been reproduced with ordinary pantothenic acid at matched or higher doses (Gaddi 1984, Rumberger 2011). The proposed mechanism — pantethine's cysteamine moiety inhibits HMG-CoA reductase and fatty acid synthesis — is moiety-specific, not vitamin-class.

contraindications

Pantothenic acid has no Tolerable Upper Intake Level; the IOM concluded that high-dose human exposure has shown no toxicity beyond occasional diarrhoea at multi-gram doses (IOM 1998). The single documented serious adverse event in the modern literature is a case report of life-threatening eosinophilic pleuropericardial effusion in a woman taking high-dose biotin and pantothenic acid together for hair growth; the effusion resolved on discontinuation (Debourdeau 2001). Pantethine specifically appears to be well tolerated at lipid-dose ranges in trials reporting adverse events comparable to placebo (Evans 2014). Standard caveat for pregnancy and lactation: the AI rises modestly (to 6–7 mg/day) and pharmacological dosing has not been studied (IOM 1998).

practicalities

Cost is trivial. Standalone pantothenic acid (calcium pantothenate, 500 mg) runs under USD 0.05 per pill at the wholesale tier; multivitamins routinely contain 5–10 mg as a free inclusion. Pantethine for lipids runs USD 20–40 per month at 600 mg/day. Topical dexpanthenol creams (Bepanthen and equivalents) are OTC across most jurisdictions and cost USD 5–15 per tube. The decision-cost of any of these is low, which is also why under-evidenced claims persist: the cost of trying is low enough that personal failure feedback is noisy.

audience

Subpopulations who might rationally consider derivative-specific use: adults with borderline dyslipidaemia who decline or are intolerant of a statin, where pantethine offers a small, real effect with a benign profile (Rumberger 2011); adults with persistent compromised skin barrier (post-procedural, atopic, irritant contact) for topical dexpanthenol (Proksch 2017); adults with mild-to-moderate acne who have exhausted first-line options and want to try an oral adjunct with a single supporting trial (Yang 2014). The general adult population does not need supplemental B₅; deficiency does not occur in mixed diets.

failure-modes

Most "failures" of B₅ supplementation are not failures of the molecule but of the expectation. The replete subject who takes a 500 mg tablet expecting an energy lift finds nothing because there is nothing to find; the lipid patient who substitutes pantothenic acid for pantethine finds nothing because the wrong molecule was taken. The acne user who runs the Leung-style mega-dose with no controls and reports improvement is regressing to mean on a famously cyclical condition. The internal coherence of "I tried B₅ and it didn't work" almost always traces to one of these three patterns.

history

Pantothenic acid was isolated by Roger Williams in 1933 as a yeast growth factor and identified as the antidermatitis factor in chicks; CoA was subsequently identified by Lipmann in 1947 (Nobel 1953) as the molecule that explained the vitamin's biochemical role. Williams's choice of name signalled how widely distributed the molecule was and predicted, correctly, that human deficiency would be vanishingly rare in any normal diet. The acne hypothesis emerged from Hong Kong (Leung) in the 1990s; the lipid hypothesis from Italian cardiology and Japanese metabolic medicine in the 1980s. Topical dexpanthenol entered the European pharmacy market under the Bepanthen brand in 1944 (Proksch 2017).

out-of-scope

Adjacent topics not covered here: pantothenate kinase-associated neurodegeneration (PKAN), a rare genetic disorder of CoA biosynthesis with a quite different therapeutic landscape; biotin's interactions with the same SMVT transporter at supraphysiological doses, more relevant to the biotin entry; broader vitamin-supplement-stack questions that belong with the multivitamin entry.

Credibility range

Optimist case

Pantothenic acid is the single biochemical entry point to CoA, and CoA is the most central low-molecular-weight cofactor in metabolism. Anywhere CoA pools or 4'-phosphopantetheine availability are limiting — chronic inflammation, mitochondrial stress, particular comorbidities — there is a defensible mechanistic argument for restoring substrate. The pantethine lipid signal is consistent across decades, replicated in different geographies, and pharmacologically coherent (cysteamine moiety acting on HMG-CoA reductase and FAS): a real, modest LDL/triglyceride drug masquerading as a supplement (Gaddi 1984, Rumberger 2011, Evans 2014). Dexpanthenol's seven-decade clinical record for skin barrier and wound care is the strongest evidence base in the family (Proksch 2017). The acne RCT, while single, was placebo-controlled and double-blinded and reported a clinically meaningful effect at gram-scale doses with no safety signal (Yang 2014).

Skeptic case

The mechanism is necessary but homeostatically defended: tissue CoA does not rise with intake in the replete, and no human deficiency has been documented in a free-living mixed-diet population since the 1940s POW reports (IOM 1998, Fry 1976). The pantethine trials are all small (n < 200), heavily industry-funded, and never tested against an active comparator; the effect at 600 mg/day is a fraction of low-dose atorvastatin in a population that would benefit more from the statin. The acne trial is a single small RCT funded by the supplement manufacturer; replication has not appeared in the decade since. The adrenal claim has no human evidence at all (Cadegiani 2016). The energy claim has been directly tested and was null (Webster 1997). The default supplement-aisle pitch is built on the mechanism word, not on the trial data, and the cumulative consumer spend on something that does almost nothing for almost everyone is itself the harm.

Author's call

For the general reader, the honest call is: you do not need to supplement pantothenic acid; you are already getting enough. The vitamin's biochemistry is genuinely central, but centrality of mechanism does not imply benefit of supplementation in the replete — that is the single most repeated marketing error in the B-vitamin category. Three carve-outs survive scrutiny: pantethine as a modest lipid-lowering option for a specific niche (not statin-eligible by choice or intolerance); topical dexpanthenol for compromised skin barrier, where the evidence is strongest; and oral high-dose B₅ for acne as a low-confidence adjunct with one supporting RCT. The adrenal claim is rejected. The energy claim is rejected. Controversy in the field is low — most nutrition reviewers reach the same call — so controversy is low; evidence is moderate, since the basics of the vitamin's role and the negligible-deficiency-risk story are extremely well established, while the derivative-specific claims are mixed.

Stakeholder + incentive map

Supplement industry. Calcium pantothenate is among the cheapest B-vitamin ingredients to source; it appears in essentially every B-complex and multivitamin SKU. The "energy" and "adrenal support" framing is load-bearing for stress / adrenal / cortisol-marketed product lines.
Pantethine manufacturers (notably Kyowa Hakko, Japan). Funded the modern North American RCTs (Rumberger 2011, Evans 2014). Trials are methodologically clean but uniformly industry-sponsored; an independent replication has not appeared.
Dermatology / consumer skincare. Bayer (Bepanthen) and successors have a 70-year commercial position in dexpanthenol; the evidence base is good but the brand-loyalty layer over it is large.
"Adrenal fatigue" practitioners. A subset of integrative-medicine and naturopathic providers organise treatment protocols around an entity that the endocrinology literature does not recognise (Cadegiani 2016); B₅ is a default component.
Regulators (IOM/NAM, EFSA). Set Adequate Intakes and declined to set ULs in the absence of toxicity data — a tacit acknowledgement that the vitamin is hard to harm someone with (IOM 1998).

Population variability

Genuine deficiency is essentially confined to severe malnutrition, alcohol use disorder with poor intake, and the experimental antagonist condition. Pantothenate kinase 2 deficiency (PKAN) is a rare neurogenetic disease of CoA biosynthesis that is mechanistically related but clinically distinct and out of scope. Pregnancy and lactation modestly raise the AI but no problem of insufficiency has been documented in well-fed populations (IOM 1998). For the derivative claims, response heterogeneity is plausible but underpowered: the pantethine lipid trials sub-grouped by baseline LDL and reported larger absolute drops in higher baselines, which is typical for lipid-active agents. The Yang acne trial restricted enrolment to mild-moderate facial acne; moderate-to-severe and inflammatory-dominant phenotypes were not tested.

Knowledge gaps

No independent (non-industry) replication of the pantethine lipid trials.
No head-to-head comparison of pantethine and a low-intensity statin in the population that would actually consider both.
The Yang acne RCT has not been replicated; mechanism (sebum lipid composition? CoA-dependent skin lipid metabolism?) is hand-wavy.
No controlled human data on pantothenic acid and any cortisol / catecholamine endpoint at any dose.
The interaction of high-dose biotin with high-dose pantothenic acid (via SMVT competition and clinical synergy) has only the Debourdeau case report; mechanism is biologically plausible but not formally studied (Debourdeau 2001).

Scope vs. brief. The brief named four consequences: CoA synthesis / energy metabolism, lipid markers at high doses, adrenal-support claims, and topical acne. All four are covered. The CoA / energy story is treated as the negative case (mechanism real, supplementation null in the replete), the adrenal claim as the negative case, and the lipid + topical + oral acne uses as the three positive carve-outs. No silent narrowing.

Editorial framing. The honest hook is debunking-with-carve-outs, not aspiration. Wrote the dream narrative on the relief lever and let the dek / tagline carry the marketing-tax frame. The pull score (2) deliberately reflects that this is a low-felt-reward entry — the reader's win is putting a bottle back on the shelf, not picking one up.

Hard scoping calls:

Treated pantethine as a derivative of B₅ inside this entry rather than splitting it. Pantethine has its own trial base and a different mechanism (cysteamine moiety), and could plausibly support its own entry one day; today the casual reader meets it through "B₅ for cholesterol" marketing, so the right place to clarify the distinction is here. Flagging for split if pantethine ever warrants standalone depth.
Treated dexpanthenol similarly — same family, different molecule, longest evidence base. Could split out if the skin-barrier / wound-care thread grows.
Did not cover PKAN (pantothenate kinase-associated neurodegeneration). Rare neurogenetic disorder, completely separate clinical surface, would mislead the casual reader if mixed in.
Did not cover SMVT pharmacology in depth — out of scope for a casual reader, lives more naturally inside the biotin entry.

Rating difficulties:

evidence: 3 was the hardest call. The basics (CoA role, dietary sufficiency, deficiency rarity) are essentially 5 — multiple decades of clean human work, IOM-grade. The derivative claims are uneven: pantethine has 3 small RCTs all manufacturer-funded; dexpanthenol has a 70-year mixed evidence base; oral acne is a single small RCT; energy + adrenal claims are null or unstudied. Landed at 3 as the honest weighted mean — not the 4 the deficiency story alone would earn, not the 2 the derivative claims alone would.
controversy: 1. Mainstream nutrition reviewers converge; the contested edges are at the margins (statin-substitute framing of pantethine, replication of Yang 2014).
applicability: 4. Treated as "supplement-curious adult" addressable audience, which matches the broad shelf presence of B-complex / energy / adrenal products. If applicability were scored on "needs to supplement," it would be 1.
health_short_term: 1 and beauty_direct: 1 are both honestly small. The dexpanthenol skin signal is real but topical and bounded; the lipid effect is functional but slow; the acne signal is single-trial. None of these justify a 2.

Future-link candidates (named in out-of-scope, not yet existing as entries): adrenal-fatigue-as-construct, biotin, niacin-for-lipids, topical retinoids, benzoyl peroxide, multivitamin-evidence-overview.

Separate-entry candidates: pantethine as a non-statin lipid agent, if the niche audience proves big enough to support its own entry; dexpanthenol topical, if the wound-care / skin-barrier thread grows.